BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 35352024)

  • 21. Functional characterization of uveal melanoma oncogenes.
    Ma J; Weng L; Bastian BC; Chen X
    Oncogene; 2021 Jan; 40(4):806-820. PubMed ID: 33262460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death.
    Ambrosini G; Musi E; Ho AL; de Stanchina E; Schwartz GK
    Mol Cancer Ther; 2013 May; 12(5):768-76. PubMed ID: 23443802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.
    Ambrosini G; Pratilas CA; Qin LX; Tadi M; Surriga O; Carvajal RD; Schwartz GK
    Clin Cancer Res; 2012 Jul; 18(13):3552-61. PubMed ID: 22550165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.
    Ambrosini G; Sawle AD; Musi E; Schwartz GK
    Oncotarget; 2015 Oct; 6(32):33397-409. PubMed ID: 26397223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071.
    Piperno-Neumann S; Larkin J; Carvajal RD; Luke JJ; Schwartz GK; Hodi FS; Sablin MP; Shoushtari AN; Szpakowski S; Chowdhury NR; Brannon AR; Ramkumar T; de Koning L; Derti A; Emery C; Yerramilli-Rao P; Kapiteijn E
    Mol Cancer Ther; 2020 Apr; 19(4):1031-1039. PubMed ID: 32029634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting primary and metastatic uveal melanoma with a G protein inhibitor.
    Onken MD; Makepeace CM; Kaltenbronn KM; Choi J; Hernandez-Aya L; Weilbaecher KN; Piggott KD; Rao PK; Yuede CM; Dixon AJ; Osei-Owusu P; Cooper JA; Blumer KJ
    J Biol Chem; 2021; 296():100403. PubMed ID: 33577798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma.
    Moore AR; Ran L; Guan Y; Sher JJ; Hitchman TD; Zhang JQ; Hwang C; Walzak EG; Shoushtari AN; Monette S; Murali R; Wiesner T; Griewank KG; Chi P; Chen Y
    Cell Rep; 2018 Feb; 22(9):2455-2468. PubMed ID: 29490280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Whole-genome CRISPR screening identifies PI3K/AKT as a downstream component of the oncogenic GNAQ-focal adhesion kinase signaling circuitry.
    Arang N; Lubrano S; Rigiracciolo DC; Nachmanson D; Lippman SM; Mali P; Harismendy O; Gutkind JS
    J Biol Chem; 2023 Feb; 299(2):102866. PubMed ID: 36596361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Uveal melanoma driver mutations in GNAQ/11 yield numerous changes in melanocyte biology.
    Perez DE; Henle AM; Amsterdam A; Hagen HR; Lees JA
    Pigment Cell Melanoma Res; 2018 Sep; 31(5):604-613. PubMed ID: 29570931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequent and Yet Unreported GNAQ and GNA11 Mutations are Found in Uveal Melanomas.
    Schneider B; Riedel K; Zhivov A; Huehns M; Zettl H; Guthoff RF; Jünemann A; Erbersdobler A; Zimpfer A
    Pathol Oncol Res; 2019 Oct; 25(4):1319-1325. PubMed ID: 29209985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma.
    Glinkina KA; Teunisse AFAS; Gelmi MC; de Vries J; Jager MJ; Jochemsen AG
    Melanoma Res; 2023 Oct; 33(5):345-356. PubMed ID: 37467061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In uveal melanoma Gα-protein GNA11 mutations convey a shorter disease-specific survival and are more strongly associated with loss of BAP1 and chromosomal alterations than Gα-protein GNAQ mutations.
    Piaggio F; Croce M; Reggiani F; Monti P; Bernardi C; Ambrosio M; Banelli B; Dogrusöz M; Jockers R; Bordo D; Puzone R; Viaggi S; Coviello D; Lanza FB; Bartolucci M; Petretto A; Mosci C; Gangemi R; van der Velden PA; Jager MJ; Pfeffer U; Amaro A
    Eur J Cancer; 2022 Jul; 170():27-41. PubMed ID: 35580369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma.
    Baqai U; Kurimchak AM; Trachtenberg IV; Purwin TJ; Haj JI; Han A; Luo K; Pachon NF; Jeon A; Chua V; Davies MA; Gutkind JS; Benovic JL; Duncan JS; Aplin AE
    J Biol Chem; 2023 Dec; 299(12):105418. PubMed ID: 37923138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutations in GNA11 in uveal melanoma.
    Van Raamsdonk CD; Griewank KG; Crosby MB; Garrido MC; Vemula S; Wiesner T; Obenauf AC; Wackernagel W; Green G; Bouvier N; Sozen MM; Baimukanova G; Roy R; Heguy A; Dolgalev I; Khanin R; Busam K; Speicher MR; O'Brien J; Bastian BC
    N Engl J Med; 2010 Dec; 363(23):2191-9. PubMed ID: 21083380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Role of Mutation Rates of GNAQ or GNA11 in Cases of Uveal Melanoma in Japan.
    Ominato J; Fukuchi T; Sato A; Yamaguchi N; Kobayashi K; Cho H; Oyama T; Ajioka Y
    Appl Immunohistochem Mol Morphol; 2018 Oct; 26(9):658-663. PubMed ID: 28248732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. YAP/TAZ Activation Drives Uveal Melanoma Initiation and Progression.
    Li H; Li Q; Dang K; Ma S; Cotton JL; Yang S; Zhu LJ; Deng AC; Ip YT; Johnson RL; Wu X; Punzo C; Mao J
    Cell Rep; 2019 Dec; 29(10):3200-3211.e4. PubMed ID: 31801083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Driver mutations in
    García-Mulero S; Fornelino R; Punta M; Lise S; Varela M; Del Carpio LP; Moreno R; Costa-García M; Rieder D; Trajanoski Z; Gros A; Alemany R; Piulats JM; Sanz-Pamplona R
    Oncoimmunology; 2023; 12(1):2261278. PubMed ID: 38126027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.
    Cheng H; Chua V; Liao C; Purwin TJ; Terai M; Kageyama K; Davies MA; Sato T; Aplin AE
    Mol Cancer Ther; 2017 Mar; 16(3):516-528. PubMed ID: 28138035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma.
    Li Y; Yang J; Zhang Q; Xu S; Sun W; Ge S; Xu X; Jager MJ; Jia R; Zhang J; Fan X
    Oncogene; 2022 Jul; 41(27):3539-3553. PubMed ID: 35697803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uveal Melanoma:
    Psinakis F; Katseli A; Koutsandrea C; Frangia K; Florentin L; Apostolopoulou D; Dimakopoulou K; Papakonstantinou D; Georgopoulou E; Brouzas D
    Anticancer Res; 2017 Oct; 37(10):5719-5726. PubMed ID: 28982892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.